<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to prospectively evaluate the efficacy of combination irinotecan and cetuximab chemotherapy in patients with pretreated <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> harboring <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> that had progressed after chemotherapy with irinotecan, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, and fluoropyrimidine were included </plain></SENT>
<SENT sid="2" pm="."><plain>KRAS status was evaluated using the Cycleave PCR method; only patients without KRAS mutations were included </plain></SENT>
<SENT sid="3" pm="."><plain>Cetuximab was administered initially at 400 mg/m² followed by weekly 250 mg/m² infusions </plain></SENT>
<SENT sid="4" pm="."><plain>Irinotecan was administered biweekly </plain></SENT>
<SENT sid="5" pm="."><plain>From October 2008 to April 2009, a total of 30 patients were enrolled </plain></SENT>
<SENT sid="6" pm="."><plain>The objective response rate was 30.0% (95% confidence interval [CI], 14.7-49.4%) and the disease control rate (complete response, partial response, or stable disease) was 80.0% (95% CI, 61.4-92.3%) </plain></SENT>
<SENT sid="7" pm="."><plain>Among the 15 patients with stable disease, 11 patients experienced &gt;10% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> shrinkage </plain></SENT>
<SENT sid="8" pm="."><plain>Median progression-free survival was 5.8 months (95% CI, 4.1-7.6) </plain></SENT>
<SENT sid="9" pm="."><plain>Median overall survival was not reached at a median follow-up of 10.1 months </plain></SENT>
<SENT sid="10" pm="."><plain>Grade 2 skin toxicity was observed in 23 patients, while no grade 3 skin toxicity was observed </plain></SENT>
<SENT sid="11" pm="."><plain>Combined irinotecan and cetuximab is effective for pretreated metastatic <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>